(Reuters) – U.S. pharmaceutical giant Pfizer and German biopharmaceutical company Biontech said on Monday that their jointly developed Omicron-derived BQ.1.1 vaccine for the new coronavirus will be administered to people aged 55 and over. It said that it increased the total antibody by nearly 9 times, which is more than about 2 times higher than when the first vaccines of both companies were administered.
Two types of vaccines were administered to about 40 people each and compared. Published in the online data archive “bioRxiv”.
In the United States, BQ. Derivative infections related to BQ.1, such as 1.1, are believed to have reached nearly half of all corona infections, and are expected to spread in Europe this winter.